Citations

Clear

1134 citation(s) found for "Su, Yan".

Evaluation Frameworks for Predictive and Generative Oncology AI: Current Standards, Cancer-Specific Gaps, and a Path Toward Clinical Use
Yost, Connor D., Callas, Bradley, Halligan, Peter, Palumbo, Peter, Rawal, Samarth, Leyfman, Yan , Yost, Connor , Leyfman, Yan , Yost, Connor , Halligan, Peter, Rawal, Samarth, Nguyen, Ryan H.

Mayo Clinic

Cancers | June 18, 2026 | Volume: 18 | Issue: 12 | Pages: 1981

10.3390/cancers18121981 | PMID 42352515 Get It

Artificial intelligence (AI) is now applied across oncology, including imaging, pathology, therapy selection, toxicity assessment, and survival modeling, and large language models (LLMs) have been adopted particularly quickly. Reported physician use of AI roughly doubled between 2023 and 2026. The frameworks used to evaluate these tools have not advanced at the same rate. Many are available, but each was designed for a single stage of the AI lifecycle, and none directly answers the question most relevant to a treating clinician: whether a given tool is appropriate for the individual patient under care. We reviewed the frameworks in current use, including TRIPOD+AI, PROBAST+AI, CLAIM, SPIRIT-AI, CONSORT-AI, DECIDE-AI, MINIMAR, and CREMLS, together with the oncology-specific ESMO EBAI and the newer LLM-specific guidance (TRIPOD-LLM, MI-CLEAR-LLM, CHART, and ESMO ELCAP). Each addresses part of the evaluation problem, but none is sufficient on its own for oncology, where the standard of care changes rapidly, assays drift, biomarker-defined subgroups are small, and a model validated in one period may perform poorly in the next. LLMs introduce additional challenges, including sensitivity to prompting, undisclosed vendor updates, behavioral drift, and hallucination rates approaching 50% on clinical quality-assurance tasks. The predictive-model frameworks were not designed to capture these failure modes. The central argument of this review is that the frameworks the field requires already exist; what is missing is their mandatory adoption. We propose that journals and regulators move from recommending these frameworks to requiring their use, and we outline a cancer-aware evaluation pathway together with the specific responsibilities of authors, reviewers, journals, and regulators in implementing it.
Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology
Johnson, Douglas, Albertini, Mark R. , Barker, C. A., Bateni, Sarah, Baumgartner, Joel, Bichakjian, Christopher, Boland, Genevieve , Chandra, Sunandana , Chen, David, Choi, Jacob, DiMaio, Dominick, Dronca, Roxana, Fleming, Martin D. , Galan, Anjela , Guild, Samantha, Hu-Lieskovan, Siwen, Karakousis, Giorgos, Kendra, Kari, Kiuru, Maija, Lange, Julie R., Lanning, Ryan, Logan, Theodore, Materin, Miguel, Nelson, Kelly, Olson, Daniel, Pa, Ott, Puzanov, Igor, Rothermel, Luke, Salama, April K., Shannon, Adrienne, Singh, Arun, Stacey, Andrew, Tsai, Katy, Wuthrick, Evan, Xing, Yan, McMillian, Nicole, Espinosa, Sara, Swetter, Susan M. , Johnson, Douglas B., Barker, Christopher A. , Baumgartner, Joel , Bhatia, Shailender , Bichakjian, Christopher K. , Chmielowski, Bartosz , DiMaio, Dominick J. , Guild, Samantha, Hu‐Lieskovan, Siwen , Karakousis, Giorgos C. , Kiuru, Maija H. , Lanning, Ryan M. , Logan, Theodore F. , Materin, Miguel Angel , Nelson, Kelly C., Olson, Daniel , Olszanski, Anthony J. , Puzanov, Igor , Rothermel, Luke D. , Salama, April K.S. , Sharma, Rohit , Wuthrick, Evan , McMillian, Nicole R.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | June 15, 2026 | Volume: 24 | Issue: 6 | Pages: 272-277

10.6004/jnccn.2026.0027 | PMID 42297031 Get It

The NCCN Guidelines for Melanoma: Cutaneous provide strategies for the diagnosis, treatment, and follow-up of patients with cutaneous melanoma, which is among the most common cancers in the United States. The outcome of cutaneous melanoma is significantly influenced by stage at initial presentation. Generally, localized disease and smaller primary tumors have been associated with more favorable prognosis. Thus, the select content featured in this issue focuses on risk factors associated with cutaneous melanoma development and which should be considered during an initial assessment. These include (1) phenotypic predispositions, (2) personal medical history or comorbidities, (3) genetic predispositions, and (4) environmental factors.
Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry
Maclachlan, Kylee , Papadimitriou, Marios , Blaney, Patrick , Baughn, Linda B. , Shekarkhand, Tala , Poos, Alexandra M. , Ziccheddu, Bachisio , Tang, Hongwei , Yan, Huihuang , Diamond, Benjamin , Zhang, Yanming , Cimera, Robert , Hultcrantz, Malin , Mailankody, Sham , Hassoun, Hani , Tan, Carlyn , Brown, Elizabeth , Winterkorn, Lara , Steinsnyder, Zoe , Vaksman, Zalman , Korde, Neha , Weinhold, Niels , Maclachlan, Kylee , Tang, Hongwei , Dogan, Ahmet , Gagler, Dylan , Boyle, Eileen M , Hultcrantz, Malin , Mailankody, Sham , Hassoun, Hani , Shah, Urvi A , Tan, Carlyn R , Brown, Elizabeth E , Winterkorn, Lara , Chu, Timothy , Steinsnyder, Zoe , Vaksman, Zalman , Davies, Faith E , Korde, Neha , Landgren, C Ola , Raab, Marc S , Lesokhin, Alexander M , Robine, Nicolas , Weinhold, Niels , Usmani, Saad , Maura, Francesco , Morgan, Gareth J , Baughn, Linda B , Diamond, Benjamin T , Blaney, Patrick , Poos, Alexandra M. , Doǧan, Ahmet , Boyle, Eileen M. , Shah, Urvi A. , Davies, Faith E. , Landgren, Ola , Raab, Marc S. , Lesokhin, Alexander M. , Usmani, Saad Z. , Maura, Francesco , Morgan, Gareth J.

Mayo Clinic

Blood Cancer Discovery | June 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: OF1-OF17

10.1158/2643-3230.bcd-25-0259 | PMID 42284538 Get It

Abstract Studies have reported conflicting findings regarding the contribution of germline variants or somatic genomic drivers to racial disparities in multiple myeloma. To comprehensively investigate somatic drivers in relation to inherited genetics in multiple myeloma, we combined newly sequenced whole-genome sequencing data with publicly available datasets (total n = 1,286). Overall, we did not identify germline or somatic genomic differences that explain the different risk of developing multiple myeloma between patients with genetic similarity to African (AFR) or European (EUR) reference populations. A difference in the detectability and timing of APOBEC-associated and germinal center mutational activity was observed. Integrating epidemiologic data and mutational signature-based temporal estimates, we challenge the assumption that individuals in the AFR group develop multiple myeloma at a younger age. Finally, we demonstrate that, with equal access to efficacious therapies, patients in the AFR and EUR groups have equivalent clinical outcomes. Significance: Multiple myeloma is reported to occur at higher rates in individuals who self-identify as non-Hispanic Black. In this large dataset, genomic drivers occur at the same rate among ancestry groups, except for APOBEC mutagenesis. With equivalent therapy, clinical outcomes did not differ for patients grouped by genetic ancestry similarity.
MCM2-7 proteins promote NF-κB transcriptional activity through cooperative promoter recruitment
Hong, Xian , Sui, Ming , Li, Qiang , Lu, Yan-Ji, Nie, Yong-Hong, Li, Y Z, YUE, Xin-xin, Xu, Jing , Billadeau, Daniel, Wang, Tao, Deng, Zhi-Hui , Wang, Tao , Li, Wenhua

Mayo Clinic

Bioscience Reports | June 11, 2026 | Volume: 46 | Issue: 7 | Pages: No page available

10.1042/bsr20260337 | PMID 42273736 Get It

Abstract The minichromosome maintenance 2-7 (MCM2-7) proteins form a hexameric protein complex that is the structural core of replicative helicase, which is essential for accurate DNA replication. While their role in replication is well-established, the biological functions of excess chromatin-bound MCM2-7 proteins remain unclear. Here, we identify a transcriptional regulatory function of MCM2-7 through its interaction with nuclear factor κB (NF-κB) p65. We demonstrate that MCM2-7 proteins and NF-κB p65 reciprocally recruit each other to target gene promoters. Consequently, MCM2-7 proteins facilitate the localization of RNA Pol II to NF-κB target gene promoters and along the gene body, thereby promoting transcription of NF-κB target genes. These findings reveal MCM2-7 proteins promote NF-κB target gene transcription by facilitating p65 and RNA Pol II recruitment, offering a potential avenue for fine-tuning NF-κB target gene transcription.
Pilot study of topical imiquimod combined with pembrolizumab for unresectable cutaneous metastatic melanoma
Parker, Joseph B., Joseph, Richard W., Suman, Vera J., Yan, Yiyi, Chen, Ruqin, Suman, Vera J. , Yan, Yiyi

Mayo Clinic

Frontiers in Oncology | June 10, 2026 | Volume: 16 | Issue: No issue available | Pages: No page available

10.3389/fonc.2026.1797703 | PMID 42358556 Get It

Cutaneous metastases occur in up to 20% of patients with advanced melanoma and can be difficult to manage with systemic therapy alone. Pembrolizumab is a standard therapy with limited local treatment options for cutaneous manifestations. Imiquimod has shown activity in other skin cancers but is less well studied in melanoma. We conducted a pilot trial to evaluate the feasibility, safety, and preliminary efficacy of combining topical imiquimod with intravenous pembrolizumab in patients with unresectable melanoma with cutaneous metastases. This was a single-center, open-label, non-randomized interventional study (NCT03276832). Eligible patients received pembrolizumab IV every 21 days plus topical imiquimod 5% applied Monday–Friday each cycle. The primary endpoint was objective response rate per RECIST v1.1. Secondary endpoints included progression-free survival, and safety. In this study, seven patients were enrolled, five were male and two females; one was Hispanic and six were non-Hispanic White. Median treatment exposure was 8 cycles. ORR was 57.1%, with 3 patients (42.9%) achieving complete response, 1 partial response, and 2 stable disease. The 7-month PFS rate was 57.1%. At study closure, 4 patients remained alive without progression, 2 were alive following progression, and 1 had died of disease. Toxicities were mostly grade 1, with fatigue and anemia most common with minimal grade 2 events. The combination of topical imiquimod and pembrolizumab was feasible, safe, and demonstrated promising antitumor activity in unresectable cutaneous melanoma. A 42.9% CR rate in this small elderly cohort supports further evaluation of local immune modulation with systemic PD-1 blockade for cutaneous melanoma.
Identification of tumor-associated antigens with multi-cancer therapeutic potential
Wickland, Daniel P. , Jessen, Erik , Nair, Asha, Necela, Brian, Lauer, Kimberly, Mangalaparthi, Kiran K., Balaya, Rex Devasahayam Arokia , Pandey, Akhilesh, Mansfield, Aaron S., Knutson, Keith L., Asmann, Yan W. , Arokia Balaya, Rex Devasahayam, Devasahayam Arokia Balaya, Rex , Necela, Brian M. , Mangalaparthi, Kiran K. , Pandey, Akhilesh, Mansfield, Aaron S., Knutson, Keith L.

Mayo Clinic

Frontiers in Immunology | June 5, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fimmu.2026.1839980 | PMID 42327740 Get It

Tumor-associated antigens (TAAs) are non-mutated antigenic peptides expressed in cancer tissue at abnormally high levels but in normal tissue either at negligible levels, during only particular developmental stages, or in a tissue-restricted manner. The shared nature of TAAs across patients makes them attractive targets for off-the-shelf immunotherapies. However, no studies have comprehensively surveyed the TAA potential of all possible wild-type peptides originating from cancer-associated genes. In this study of 16 cancer tissue types and 39 normal tissue types, we analyzed the expression profiles of protein-coding genes to identify those with aberrantly high RNA levels across multiple solid tumor types and low RNA levels across all normal tissue types examined. We then developed a score to quantify tumor specificity of gene expression. Compared to previously reported TAA genes, those we identified exhibited substantially greater tumor specificity. Seven of these genes demonstrated consistently elevated expression in at least five tumor types and minimal expression across all non-immune-privileged normal tissues. To assess Human Leukocyte Antigen (HLA) class I presentation potential of the multi-cancer-associated genes, we computationally predicted the binding affinities between the most common class I HLA alleles and all possible wild-type TAA epitopes of 8–11 amino acids arising from those genes. We then applied rigorous filtering criteria to prioritize the most promising multi-cancer TAA peptide candidates and evaluated their HLA binding and cell-surface presentation using T2 and immunopeptidome analysis. Our results highlight new potential targets for multi-cancer immunotherapies.
Spatially resolved single-cell landscape of tumor immunotypes reveals the central role of interferon signaling and plasmacytoid dendritic cells in triple-negative breast cancer
Liu, Y H, Carter, Jodi M. , Ma, Yaohua, Deshmukh, Sachin K, Sledge, George W, Kachergus, Jennifer M, Shi, Ji , Gregory, Mark, Gong, Jingjing, Joensuu, H, Perez, EA, Stover, Daniel, Carey, Lisa, Sikov, William M. , Leon-Ferre, Roberto, Knutson, Keith L. , Boughey, Judy C, Ingle, J , Couch, Fergus J, Asmann, Yan W. , Goetz, Matthew P, Thompson, E Aubrey, Chumsri, Saranya, Liu, Yi , Liu, Yi , Wrangle, John M , Stover, Daniel G , Leon-Ferre, Roberto , Knutson, Keith L. , Ingle, James N. , Carter, Jodi , Balko, Justin M. , Kachergus, Jennifer M., Joensuu, Heikki , Perez, EA, Carey, Lisa, Boughey, Judy C. , Kalari, Krishna R. , Couch, Fergus J. , Goetz, Matthew P. , Thompson, E. Aubrey , Chumsri, Saranya

Mayo Clinic

Journal for ImmunoTherapy of Cancer | June 3, 2026 | Volume: 14 | Issue: 6 | Pages: e014020

10.1136/jitc-2025-014020 | PMID 42236117 Get It

Background Tumor-infiltrating lymphocytes (TILs) are established determinants of clinical outcomes in breast cancer. 1–6 While stromal TILs (sTILs) are commonly evaluated due to easier scoring and higher interobserver reproducibility, intraepithelial TILs may provide additional insights into anti-tumor immunity. 7 We aimed to comprehensively characterize immunotype-associated cellular landscapes in triple-negative breast cancer (TNBC) and identify features associated with clinical outcomes. Methods 212 TNBC tumors were classified into three immunotypes based on immune infiltrate location and density: immune desert (ID), immune excluded (IE), and immune inflamed (IN). 8 Single-cell spatial transcriptomics was performed on 75 tumors to define the cellular composition and functional states of the tumor microenvironment across immunotypes. Findings were validated and integrated with bulk RNA sequencing data and clinical outcome datasets from FinXX, CALGB-40603, I-SPY 2, and Real-World Clinico-Genomic Data (RWCGD) cohorts. Results Patients with IN tumors had significantly improved outcomes compared with ID tumors. Despite high sTILs, IE tumors showed poor outcomes similar to ID tumors. Single-cell spatial analysis revealed that ID and IE tumors exhibited reduced major histocompatibility complex I/II expression and fewer tumor-resident plasmacytoid dendritic cells (pDCs) compared with IN tumors, which were enriched for interferon-alpha (IFNα) and interferon-gamma (IFNγ) responses. High IFN response scores were associated with favorable outcomes across multiple therapy types in independent datasets. Deconvolution of RWCGD bulk RNA-seq data confirmed that pDC abundance correlated with improved outcomes specifically in hormone receptor–negative subtypes. Conclusions Our study highlights pDCs and IFN signaling as hallmarks of effective anti-tumor immunity in TNBC. Immunotype-based profiling underscores the limited prognostic value of sTILs alone in immune-excluded tumors and supports pDCs and IFN pathways as potential biomarkers for prognosis and therapeutic development in TNBC.
Infertility and age of menopause in a longitudinal cohort of women with primary infertility
Dyre, Lillian , Li, Yan, Sadecki, Emily J., Zhao, Yulian, Stewart, Elizabeth A., Dyre, Lillian J , Ainsworth, Alessandra J. , Sadecki, Emily N. , Stewart, Elizabeth A.

Mayo Clinic

Menopause | June 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/gme.0000000000002809 | PMID 42228436 Get It

Objectives: To analyze the association between primary infertility and infertility type with the age of natural menopause. Methods: This is a retrospective cohort study reviewing a subset of women from the Mayo Primary Infertility Cohort (MPIC). The MPIC is a cohort of 1,001 women diagnosed with primary infertility and 1,001 age-matched referent women. In this study, we included all women at risk for natural menopause and further evaluated those who had reported natural menopause in the medical record. We compared the risk of natural menopause using Cox proportional hazard models with infertility status and infertility type as covariates. In those with documented menopause during the study period, the association between primary infertility and early and premature menopause was analyzed with χ 2 testing. We evaluated the association between age at natural menopause, primary infertility status, and infertility type in this group using linear regression. Results: In all, 461 women with primary infertility, with 530 referent individuals, were at risk of natural menopause, and of these, 340 women with infertility and 346 referent women underwent documented natural menopause on review of medical records. Women with primary infertility had an increased risk of natural menopause (hazard ratio: 1.25, 95% CI: 1.06-1.46) and underwent menopause 1 year earlier than referent individuals (β=−1.17, 95% CI: −1.82 to −0.52) after adjustment for body mass index, tobacco use, race, menstrual cycle regularity, and previous contraception use. Women with primary infertility were more likely to undergo early menopause (age 40-45) than referent women (7.6% vs. 3.0%, P =0.01). Compared with referent women, women with endometriosis underwent menopause 2.75 years earlier (95% CI: −4.38 to −1.13, P =0.0009), and women with unexplained infertility underwent menopause 1.45 years earlier (95% CI: −2.26 to −0.64, P =0.0005). Conclusions: Women with primary infertility had an increased risk of early menopause and collectively underwent menopause 1 year earlier than women without a history of primary infertility.
Shifting Patterns of Colorectal Cancer Burden in the United States (1999–2023): Implications for Precision Medicine Strategies and Drug Resistance in Early-Onset Colorectal Cancer
Sun, C J , Liu, Li , Lees, Elizabeth , Billstein, Laura , Zou, Yuntao , Fickel, Abigail, Yan, Yan , Wang, Yichen, Vinh, Tuan, Travers, paul, Kumbhari, Vivek , Huang, Yuting , Travers, Paul , Lees, Elizabeth H , Billstein, Laura E, Travers, Paul M , Huang, Yuting , Yan, Yan , Fickel, Abigail

Mayo Clinic

Cancers | May 29, 2026 | Volume: 18 | Issue: 11 | Pages: 1768

10.3390/cancers18111768 | PMID 42279351 Get It

Background: Colorectal cancer (CRC) remains one of the common causes of cancer-related morbidity and mortality in the United States. Emerging increases in early-onset CRC and persistent disparities remain major public health concerns. Objective: To characterize long-term CRC incidence and mortality trends in the United States, with particular emphasis on identifying demographic groups experiencing rising or plateauing disease burden. Methods: We conducted a population-based ecological study using CRC incidence data from the United States Cancer Statistics database (1999–2022) and mortality data from CDC WONDER (1999–2023). Temporal trends were evaluated using Joinpoint regression to estimate annual percent change (APC) and average annual percent change (AAPC), stratified by age, sex, race/ethnicity, and urbanization level. Results: Overall CRC incidence and mortality declined during the study period (both AAPC approximately −2.08%). However, incidence increased significantly among adults younger than 55 years, particularly those aged 20–24 years. Mortality also increased among younger adults aged 25–44 years and remained elevated among individuals aged 45–54 years. Non-Hispanic Black individuals consistently experienced the highest incidence and mortality rates. Mortality declines plateaued in several older age groups after 2018–2020. Conclusions: Despite overall improvements in CRC burden, increasing incidence and mortality among younger adults and persistent disparities highlight the need for risk-stratified prevention, earlier detection strategies, and tailored therapeutic approaches.